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Introduction. Primary-prevention by prophylactic vaccination 
against HPV-related cancers and HPV-based screening programs 
are based on HPV-type distribution in immunocompetent individ-
uals. HIV-infected women are at high risk of invasive HPV-dis-
ease sustained by a broader range of HPV-types and have higher 
multi-type infection rates than immunocompetent hosts.  
Methods. This is a cross-sectional analysis of High Risk HPV 
(HR HPV) type distribution in 805 HIV+ women (HIW) compared 
with a control group of 1402 immunocompetent HIV- women 
(SPW) enrolled in the VALHIDATE study in order to define HPV 
type-specific distribution according to cytology.
Results. HIW had a 3.8, 3.6, and 2.7 times higher risk of atypi-
cal squamous cells of undetermined significance (ASCUS), low-
grade squamous intraepithelial lesion (LSIL) and high grade 
squamous intraepithelial lesion (HSIL) than SPW respectively. 
HPV-DNA prevalence was 28.4% in HIW and 11.81% in SPW 
(p<0.0001). The prevalence of infection increased from normal 
cytology to HSIL both in HIW (from 21.45% to 90.91%) and SPW 
(from 9.54% to 75%). The OR for women with normal cytology 
of having a positive HPV-DNA test result of was 2.6 times higher 
in HIW than in SPW. The cumulative prevalence of HPV-16/18 in 
HSIL is much lower in HIW (36.4±28.4) than SPW (62.5±33.5).
Conclusions. A higher prevalence of infection and broader 
HPV type distribution were observed in HIV+ women compared 
to the general population. More than 60% of HSIL lesions of 
HIW patients are caused by single or multi-type infections from 
non-HPV16/18 HPVs. The potential 9v-HPV vaccine coverage 
could be even higher than that expected for the general popula-
tion given the wide panel of HPV-types observed in the HSIL of 
HIV+ women.
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Summary
Introduction
Thirteen Human Papillomavirus (HPV) genotypes 
classified as carcinogenic and probably carcinogenic 
(group  1 and 2A) and six other HPV types with an 
invasive cervical cancer (ICC)/normal cytology ratio 
greater than 1.0, classified as possibly carcinogenic 
genotypes (HPV 26, 30, 67, 69, 73, and 82 – group 
2B) are the cause of more than 90% of all ICCs world-
wide [1, 2]. 
Their prevalence varies widely across world regions, but 
HPV-16 and -18 infections are the most prevalent and 
carcinogenic all over the world. Apart from the HPV 
type there are several co-factors that can contribute to 
invasive evolution [3].
Women affected by HIV/AIDS are at higher risk of in-
vasive disease which is mainly due to the extent of im-
mune-depression [4, 5]. However, the broader range of 
HPV types sustaining infections and the higher rate of 
multi-type infections in women living with HIV/AIDS 
could differently affect HPV type-specific carcinogenic-
ity [6-8]. This is particularly relevant for cervical cancer 
prevention in immune-compromised hosts: in fact both 
vaccine primary prevention and HPV-based screening 
programs are based on the HPV-type distribution in im-
munocompetent individuals.
Three different HPV vaccines have been approved and 
licensed by the European Medicines Agency (EMA) 
and are available in Italy: the 2-valent (Cervarix®, GSK 
biologicals) vaccine, which prevents infections with 
High Risk HPV (HR HPV) types 16 and 18; the 4-va-
lent vaccine (Gardasil®, Merck, Sanofi Pasteur MSD) 
which also targets Low Risk HPV (LR HPV) types 6 
and 11 and the 9-valent vaccine (Gardasil9®, Merck, Sa-
nofi Pasteur MSD) which, in addition to the four types 
of the 4-valent vaccine, also targets five additional HR 
HPV types (31, 33, 45, 52, and 58). Several studies [9, 
10] have indicated that using a 9-valent vaccine could 
improve the prevention of invasive cervical cancers 
worldwide from 70% to 90%.
This paper reports a cross-sectional analysis of HPV-
type distribution in HIV infected Women (HIW) com-
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pared with a control group of immunocompetent HIV-
negative women enrolled in the eVALuation and moni-
toring of HPV infections and relATEd cervical diseases 
(VALHIDATE) study [11]. The VALHIDATE study 
[11] was a 5-year (Dec. 2010-Dec.2015) multicenter 
open prospective cohort study aimed at gaining insight 
into the molecular epidemiology of HPV infection and 
cervical diseases in high-risk women in the Lombardy 
Region, Italy. HIW aged 26-64 years were one of the 
high-risk cohorts of the study. The control group was 
composed of women in the same age group attending 
spontaneous Pap screening-programs (SPW). 
The aim of the study was to evaluate HPV type-specific 
distribution according to cytology among HIV infected 
women. Moreover, these data will enable us to establish 
the pre-vaccine type-specific prevalence of HPV–associ-
ated diseases in this population in order to evaluate the 
potential impact of the newly approved 9-valent HPV 
vaccine.
Methods
Study design
With the aim of evaluating the baseline HPV type-spe-
cific distribution stratified by the cervical cytological 
results, HIV-infected women (HIW) were compared 
with the control group (SPW). HIW and SPW cohorts 
were recruited consecutively for 12 months from 3 In-
fectious Diseases Units and 4 Gynecology Units of the 
four general hospitals located in Lombardy participat-
ing in the VALHIDATE study [11]. In particular, HIW 
were recruited from those followed up for HIV infec-
tion and SPW from those attending a spontaneous Pap 
screening program. Exclusion criteria were: history 
of histologically proven grade  II or higher Cervical 
Intraepithelial Neoplasia (CIN) requiring treatment, 
pregnancy at the time of enrollment, inability to pro-
vide informed consent. 
The protocol enrollment was approved by the Sacco 
Hospital Ethical Committees (Resolution n174/2010, 
9 March 2010) and all participants provided written in-
formed consent.
A total of 828 HIW and 1423 SPW were enrolled in 
the VALHIDATE study. The consenting women un-
derwent basal co-testing with conventional Pap tests 
and HPV-DNA testing/genotyping. The cervical brush 
(Cytobrush Plus MedscandW Medical AB) sample 
collected at the baseline visit was used to perform 
the conventional Pap smear and then immersed and 
stored in a PreservCyt solution (ThinPrep® Pap Test, 
Hologic Italia Srl) to be analyzed for HPV-DNA and 
HPV genotyping. 
The Pap tests were evaluated according to the 2001 
Bethesda System terminology [12] by expert cyto-
pathologists from the participating Centers. The cas-
es were classified according to cytology at baseline 
evaluation as normal, atypical squamous cells of un-
determined significance (ASCUS), low-grade squa-
mous intraepithelial lesions (LSIL) and high-grade 
SIL (HSIL).
DNA extraction, HPV detection and 
genotyping
DNA was extracted with a commercial kit (NucliS-
ENS® EasyMAG®, bioMérieux, Lyon, France) and 
HPV-DNA was detected through PCR amplification 
of a 450 bp segment of ORF L1 using the degenerate 
primer pair ELSI-f and ELSI-r in the central reference 
laboratory of the University of Milan [11, 13]. HPV 
genotyping was performed on HPV-DNA positive cer-
vical brushes using the commercially available Inno-
LiPA® HPV Genotyping Extra (Innogenetics N.V., 
Belgium) method in the microbiology laboratories 
of the participating Centers. This test allows for the 
identification of 27 HPV types. All of the HPV-DNA 
positive cervical samples resulted as non-typeable 
by the Inno-Lipa test (HPV-X) were subjected to the 
Restriction Fragment Length Polymorphism (RFLP) 
type analysis which is capable of identifying all types 
of the High-Risk clade (HR-clade) and Low-Risk 
(LR) types of the alpha genus according to the 2011 
IARC classification [1, 14].
Statistical analysis
HPV-DNA prevalence and type-specific HPV prevalence 
were expressed as crude proportions with corresponding 
95% confidence intervals (95%CI) calculated assum-
ing a normal distribution. The data are presented as the 
median (interquartile range, IQR) and percentages (with 
95%CI) as appropriate. Comparisons between groups 
were made using the Chi-square test or Fisher’s exact 
test. A P-value less than 0.05 was considered statistically 
significant (two-tailed test). All of the statistical analy-
ses were performed using GraphPad Prism version 4.02 
for Windows, GraphPad Software, San Diego California 
USA (www.graphpad.com).
Results
Cytological results
Cytological results are provided for 805 HIW (97.2%) 
and 1402 SPW (98.5%). Women included in the HIW 
group had an overall 3.7-fold increased risk of AS-
CUS, a 3.6-fold increased risk of LSIL and a 2.7-fold 
increased risk of HSIL than those included in the control 
SPW group (Tab. I).
Human Papillomavirus infection by 
cytological status
HPV-DNA prevalence was 28.4% (95%CI 25.32-31.48) 
among HIW and 11.81% (95%CI 10.14-13.49) among 
SPW (p < 0.0001). HPV prevalence increased with the 
progression of the severity of cytological abnormali-
ties from 21.45% to 90.91% in HIW and from 9.54% to 
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75% in SPW in normal cytology and HSIL respectively 
(Fig. 1). 
The OR for women with normal cytology of having a 
positive HPV-DNA was 2.6 times higher in HIW (95%CI 
2.0-3.3) than in SPW.
Different HPV-DNA prevalences were found for AS-
CUS and LSIL, while no differences were observed for 
HSIL lesions between the two groups (Tab. II).
HPV typing by cytological status 
Type-specific HPV prevalence is reported in Fig 2a: 
HPV-16 was the most prevalent type which was detected 
in 4.74% of HIW and in 4.61% of SPW. No significant 
differences were observed in the patterns of distribution 
of the HIW and SPW groups, except for the identifica-
tion of infections sustained by HPV-67 and HPV-34 in 
HIW, absent in SPW and infections by HPV- 42 and 
HPV-72 types in SPW, absent in HIW. 
HPV typing stratified by cervical cytological results 
(Fig. 2b) showed very similar patterns in HIW and SPW 
with normal cytology. There is a lack of data concerning 
women with abnormal cytological results therefore we 
were unable to establish a different distribution pattern; 
however, HPV-16 is by far the most common type of 
HPV in women with abnormal cytology (any grade SIL, 
Fig. 2c) in SPW, while HPV-16 prevalence is similar to 
other high-risk HPV types (HPV-52, HPV-33 and HPV-
66) in HIW. Several other HR-HPV types have been re-
ported in HIW patients with cytological abnormalities 
(Fig 2c-2d). HSIL lesions sustained by non-HPV-16/18 
types were 16.7% (1 out of 6) in SPW and 70% (7 out 
of 10) in HIW.
The cumulative prevalence of the two main oncogenic 
types (HPV-16/18), broken down by cytological out-
come, is lower in LSIL and HSIL among the HIW than 
in the SPW and the general Italian population (Fig. 3).
Tab. I. Normal and abnormal cytological results in 805 HIW and 1402 SPW at the baseline evaluation.
Cytology
HIW
(n 805)
% 95%CI
SPW
(n 1402)
% 95%CI P value
OR
95%CI
Normal 678 84.22 81.71% 86.74% 1332 95.01 93.87% 96.15% ref 1
ASCUS 46 5.71 4.11% 7.32% 24 1.71 1.03% 2.39% < 0.0001
3.765
2.279 to 6.222
LSIL 70 8.70 6.75% 10.64% 38 2.71 1.86% 3.56% < 0.0001
3.619
2.412 to 5.430
HSIL 11 1.37 0.56% 2.17% 8 0.57 0.18% 0.96% 0.0488
2.701
1.081 to 6.749
Fig. 1. Prevalence of HPV-DNA positive samples by cytology in HIW and SPW.
Tab. II. Prevalence and OR with 95%CI of HPV-DNA by cytology in the HIW and SPW.
Cytology HIW % SPW % P  value OR 95%CI
Normal 145 21.45 127 9.54 REF 1
ASCUS vs normal 19 42.22 6 25.0 0.0351 2.774 1.074 to 7.161
LSIL vs normal 54 77.14 26 68.42 0.0290 1.819 1.076 to 3.076
HSIL vs normal 10 90.91 6 75.0 0.6082 1.460 0.5159 to 4.130
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Fig. 2. Prevalence of HPV types in the whole population of HIW and SPW enrolled (a) broken down according to cytology (b, c, d).
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Multi-type HPV infections (2 to 9 HPV types) occurred 
in 54.62% (95%CI 4.68-63.57) and 37.38% (95%CI 
28.22-46.55) of HIW and SPW with normal cytology 
respectively (p 0.011). No differences were observed in 
the prevalence of multi-type HPV infections in women 
with cytological lesions (any grade or HSIL) (Table III).
Infection from vaccine HPV-types in women 
with normal cytology
No differences were observed in the proportion of infec-
tions sustained by at least one of the HPV types included 
in 2v-, 4v-, or 9v-HPV vaccines between HIW and SPW 
with normal cytology: 20.0% vs 23.62% for 2v-, 26.90% 
vs 27.56% for 4v-, and 51.7% vs 55.9% for 9v-HPV 
vaccine respectively. A highly significant difference in 
potential coverage was observed when we compared the 
9v-HPV vaccine with the 2v- and 4v-HPV vaccines in 
both HIW and in SPW (Fig 4).
Discussion and conclusions
Worldwide, 69.4% of invasive cervical cancers are caused 
by HPV-16/18 infections [15]. In Italy, current estimates 
indicate that approximately 3.3% of females with normal 
cytology were infected with these two genotypes and 
the prevalence increased with disease progression  [15]. 
The data reported in our study closely resemble the fig-
ures for SPW, even a slightly lower prevalence of HPV 
infection was observed in women with normal cytol-
ogy; a comparable distribution of HPV types in women 
with normal cytology was found for HIW as well as a 
relatively lower presence of HPV-16/18 infections in the 
HSIL lesions compared to the Italian figures. HPV type 
distribution stratified by cytological results showed a sub-
stantial equivalence between women with HIV and SPW 
in normal cytology: HPV-16 is the most common viral 
type in both populations, followed by HPV-52, 66, 31, 53 
for SPW and by HPV-66, 53, 52, 31 for HIW. Due to the 
Fig. 3. Prevalence of HPV-16/18 infections by cytology in HIW, SPW and general Italian population [15].
Tab. III. Comparison of multi-type HPV infections according to cytology in HIW and SPW.
Multi-type HPV/
HPV+ve 
Prevalence 95%CI P value OR (95%CI)
Normal 
cytology
HIW
SPW
65/119
40/107
54.62%
37.38%
45.68%
28.22%
63.57%
46.55%
0.0112
2.016 (1.184 to 3.435)
ref
Any SIL
HIW
SPW
40/75
15/36
53.33%
41.67%
42.04%
25.56%
64.62%
57.77%
0.3117
1.600 (0.7166 to 3.572)
ref
HSIL
HIW
SPW
4/10
1/6
40.00%
16.67%
9.64%
13.15%
70.36%
46.49%
0.5879
3.333 (0.2756 to 40.31)
ref
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limited number of cases with abnormal cytology observed 
in this study, it was impossible to identify statistically 
significant differences of distribution between HIW and 
SPW. However, although HPV-16 is by far the most com-
mon type expressed in HSIL of SPW, there is a greater 
heterogeneity of genotypes in women with HIV infec-
tion and HSIL. Keller et  al.  [16] highlighted that HIV-
infected women with HPV-16 infection and normal Pap 
test results have a similar pre-cancer risk as those with 
LSIL and therefore referral for colposcopy is warranted. 
However the presence of non HPV-16/18 infections was 
observed in 70% and 16.7% of HSIL in HIW and SPW 
respectively. McKenzie et al.  [17] reported that cervical 
dysplasia specimens from 23 HIV infected women were 
infected (55%) by non-16/18 high-risk HPV types. If 
confirmed by larger cohorts, this finding may have ma-
jor implications in the screening and triage strategies for 
women infected with HIV.As described by several Au-
thors [18-19], it was observed that HIV-infected women 
have a higher prevalence of HPV and multi-type infec-
tions than the control group. A high prevalence of rare 
HPV types was detected in HIW, both in normal cytology 
and in cervical abnormalities and to date little is known 
about their carcinogenicity. The IARC classification and 
the analysis of rare HPV types show a wide variability in 
the carcinogenic potential of the rare and common HPV 
types found in normal cytology [1, 2]. In HIV-infected 
women, variability towards oncogenesis can be further 
influenced by the simultaneous presence of other cofac-
tors, in particular cell-mediated immunosuppression [5], 
while the additional risks associated with each HPV type 
in multi-type infections is difficult to establish. Although 
no statistically significant differences were found due to 
lack of data, the description of viral types in the cervical 
specimens of HIV-infected women and correlation with 
the severity of cytological lesions can contribute to the 
mapping of HPV-related pre-invasive or invasive disease 
and provide a better risk stratification of disease evolution 
in HIV-infected women. Even in the context of primary 
prevention through vaccination, the wide distribution of 
viral types found in high-grade lesions of HIV-infected 
women demonstrates the need for multivalent vaccines. 
This means that a primary prophylaxis with a 9v-HPV 
vaccine could have prevented infections in over 50% of 
the women included in this study, whether HIV infected 
or not. The assessment of the impact of HPV vaccines in 
the study population shows how immunization with a 9v-
HPV-vaccine could prevent a significantly higher propor-
tion of viral infections, both in HIV-infected people and 
in the control population, than 2v- and 4v-HPV vaccines. 
The ICC preventable fraction in the general population 
increased by 12-19% when the 9v-HPV vaccine was 
introduced due to the addition of 7 high risk HPVs to 
the 2v or 4vHPV vaccines [10, 20, 21] which could be 
even higher in HIV-infected people considering the wide 
range of HPV types observed in progressive diseases.
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